Outcomes of patients treated with the everolimus-eluting stent versus the zotarolimuseluting stent in a consecutive cohort of patients at a tertiary medical center

Vascular Health and Risk Management

Volumn 8, Issue 1, 2012, Pages 205-211

  Shammas, Nicolas W ^a   Shammas, Gail A ^a   Nader, Elie ^a   Jerin, Michael ^a   Mrad, Luay ^a   Marogil, Peter ^a   Henn, Courtney ^a   Dvorak, Alex ^a   Chintalapani, Archana ^a   Meriner, Susan ^a  

^a MIDWEST CARDIOVASCULAR RESEARCH FOUNDATION   (United States)

Author keywords

Coronary stent; Drug eluting stent; Everolimus; Outcome; Stent thrombosis; Target lesion revascularization; Zotarolimus

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; EVEROLIMUS; ZOTAROLIMUS; CARDIOVASCULAR AGENT; DRUG DERIVATIVE; RAPAMYCIN;

ACUTE DISEASE; AGED; ARTICLE; CARDIOVASCULAR RISK; CAUSE OF DEATH; CONTROLLED STUDY; DRUG ELUTING STENT; FEMALE; FOLLOW UP; HEART DEATH; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MORTALITY; OUTCOME ASSESSMENT; RETROSPECTIVE STUDY; RISK ASSESSMENT; STENT THROMBOSIS; TREATMENT FAILURE; CHI SQUARE DISTRIBUTION; COMPARATIVE STUDY; CORONARY ARTERY OBSTRUCTION; INSTRUMENTATION; KAPLAN MEIER METHOD; MIDDLE AGED; RESTENOSIS; THROMBOSIS; TIME; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME; UNITED STATES;

AGED; AGED, 80 AND OVER; ANGIOPLASTY, BALLOON, CORONARY; CARDIOVASCULAR AGENTS; CHI-SQUARE DISTRIBUTION; CORONARY RESTENOSIS; CORONARY STENOSIS; DRUG-ELUTING STENTS; FEMALE; HUMANS; IOWA; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; RETROSPECTIVE STUDIES; SIROLIMUS; THROMBOSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84863195340     PISSN: 11766344     EISSN: 11782048     Source Type: Journal    
DOI: 10.2147/VHRM.S30122     Document Type: Article

References (16)

1. Meredith I, Rothman M, Erglis A, et al. E-Five Investigators. Extended follow-up safety and effectiveness of the Endeavor zotarolimus-eluting stent in real-world clinical practice: two-year follow-up from the E-Five Registry. Catheter Cardiovasc Interv. 2011;77:993-1000.
2. Fajadet J, Wijns W, Laarman GJ, et al. Long-term follow-up of the randomised controlled trial to evaluate the safety and efficacy of the zotarolimus-eluting driver coronary stent in de novo native coronary artery lesions: five year outcomes in the ENDEAVOR II study. Euro Intervention. 2010;6:562-567.
3. Serruys P, Ong A, Piek JJ, et al. A randomized comparison of a durable polymer everolimus-eluting stent with a bare metal coronary stent: The SPIRIT first trial. Euro Intervention. 2005;1:58-65.
4. Tsuchida K, Garcia-Garcia HM, Ong AT, et al. Revisiting late loss and neointimal volumetric measurements in a drug-eluting stent trial: analysis from the SPIRIT FIRST trial. Catheter Cardiovasc Interv. 2006;67:188-197.
5. Kandzari DE, Leon MB, Popma JJ, et al. Comparison of zotarolimuseluting and sirolimus-eluting stents in patients with native coronary artery disease: a randomized controlled trial. J Am Coll Cardiol. 2006;48:2440-2447.
6. Leon MB. Endeavor clinical trial program. Available from: http://www.crtonline.org/flash.aspx?PAGE_ID=4728. Accessed October 16, 2007.
7. Stone GW, Midei M, Newman W, et al. SPIRIT III Investigators. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial. Circulation. 2009;119:680-686.
8. Herrador JA, Fernandez JC, Guzman M, et al. Comparison of zotarolimusversus everolimus-eluting stents in the treatment of coronary bifurcation lesions. Catheter Cardiovasc Interv. 2011;78:1086-1092.
9. Serruys PW, Silber S, Garg S, et al. Comparison of zotarolimuseluting and everolimus-eluting coronary stents. N Engl J Med. 2010;363:136-146.
10. Leon M. LBCT III, Session 3014. Presented at the American College of Cardiology 60th Annual Scientific Sessions, April 2-5, 2011, New Orleans, LA.
11. Food and Drug Administration. Circulatory System Devices Panel Meeting. Available from: http://www.fda.gov/ohrms/dockets/ac/cdrh06.html#circulatory. Accessed February 9, 2007.
12. Brener SJ, Prasad AJ, Khan Z, Sacchi TJ. The relationship between late lumen loss and restenosis among various drug-eluting stents: a systematic review and meta-regression analysis of randomized clinical trials. Atherosclerosis. 2011;214:158-162.
13. Leon MB, Mauri L, Popma JJ, et al. ENDEAVOR IV Investigators. A randomized comparison of the ENDEAVOR zotarolimus-eluting stent versus the TAXUS paclitaxel-eluting stent in de novo native coronary lesions 12-month outcomes from the ENDEAVOR IV trial. J Am Coll Cardiol. 2010;55:543-554.
14. Leon MB, Nikolsky E, Cutlip DE, et al. ENDEAVOR IV Investigators. Improved late clinical safety with zotarolimus-eluting stents compared with paclitaxel-eluting stents in patients with de novo coronary lesions: 3-year follow-up from the ENDEAVOR IV (Randomized Comparison of Zotarolimus- and Paclitaxel-Eluting Stents in Patients With Coronary Artery Disease) trial. JACC Cardiovasc Interv. 2010;3:1043-1050.
15. Hermiller JB, Nikolsky E, Lansky AJ, et al. Clinical and angiographic outcomes of elderly patients treated with everolimus-eluting versus paclitaxel-eluting stents: three-year results from the SPIRIT III randomised trial. Euro Intervention. 2011;7:307-313.
16. Généreux P, Palmerini T, Caixeta A, et al. SYNTAX score reproducibility and variability between interventional cardiologists, core laboratory technicians, and quantitative coronary measurements. Circ Cardiovasc Interv. 2011;4:553-561.